Takeda signs $882m rare disease alliance with Oxford biotech...

Allergan bolsters aesthetics pipeline with Exicure hair loss...

Focus day announced for SMi’s 11th annual RNA Therapeutics c...

SMi Reports: RNA Therapeutics conference and focus day to return on February 2020, in London

2nd RNA Targeted Drug Discovery Summit

At a time when the previously untapped drug discovery opportunity promised within RNA opens up, the 

BMS looks to RNA splicing to boost immunotherapies

Bristol-Myers Squibb’s quest to claim dominance in the immunotherapy space continues through a new collaboration with Eisai and its US-based precision medicine subsidiary H3 Biomedicine to

Dicerna agrees another gene-silencing deal, this time with L...

Eli Lilly has agreed a broad collaboration with Dicerna, sealing the deal with a $100 million equity stake in the RNA interference specialist.